UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

Cancer research (Chicago, Ill.), 2008-03, Vol.68 (6), p.1953-1961

2008

Volltextzugriff (PDF)

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3238-3247

2004

Volltextzugriff (PDF)

Targeting Protein Translation in Human Non-Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression

Cancer research (Chicago, Ill.), 2007-12, Vol.67 (23), p.11300-11308

2007

Volltextzugriff (PDF)

Mechanisms of resistance to vascular endothelial growth factor blockade

Cancer, 2012-07, Vol.118 (14), p.3455-3467

2012

Volltextzugriff (PDF)

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers

Clinical cancer research, 2018-04, Vol.24 (8), p.1954-1964

2018

Volltextzugriff (PDF)

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (7), p.2854-2860

2005

Volltextzugriff (PDF)

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib

Journal of thoracic oncology, 2013-06, Vol.8 (6), p.693-702

2013

Volltextzugriff (PDF)

Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

Clinical lung cancer, 2006-12, Vol.8, p.S7-S14

Perez-Soler, Roman

2006

Volltextzugriff (PDF)

Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

Clinical cancer research, 2007-06, Vol.13 (11), p.3413-3422

2007

Volltextzugriff (PDF)

The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer

Clinical cancer research, 2004-06, Vol.10 (12), p.4238s-4240s

Roman Perez-Soler

2004

Volltextzugriff (PDF)

Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells

The Journal of biological chemistry, 2003-09, Vol.278 (36), p.33714-33723

2003

Volltextzugriff (PDF)

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Oncotarget, 2016-05, Vol.7 (20), p.28976-28988

2016

Volltextzugriff (PDF)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

PloS one, 2016-07, Vol.11 (7), p.e0160004

2016

Volltextzugriff (PDF)

The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

Clinical cancer research, 2011-11, Vol.17 (21), p.6766-6777

2011

Volltextzugriff (PDF)

Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis

Blood, 2004-11, Vol.104 (9), p.2746-2751

2004

Volltextzugriff (PDF)

Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer

Clinical cancer research, 2011-02, Vol.17 (4), p.690-699

2011

Volltextzugriff (PDF)

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

Clinical lung cancer, 2004-12, Vol.6 Suppl 1, p.S20-S23

Perez-Soler, Roman

2004

Volltextzugriff (PDF)

Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung

Clinical cancer research, 2007-04, Vol.13 (8), p.2414-2421

2007

Volltextzugriff (PDF)

Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer

Clinical cancer research, 2007-08, Vol.13 (15), p.4589s-4592s

Roman Perez-Soler

2007

Volltextzugriff (PDF)

Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines

Clinical cancer research, 2003-03, Vol.9 (3), p.1145-1154

2003

Volltextzugriff (PDF)

Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist‐patient treatment discussions

Psycho-oncology (Chichester, England), 2017-07, Vol.26 (7), p.1050-1052

2017

Volltextzugriff (PDF)

Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects

PloS one, 2014-10, Vol.9 (10), p.e109874

2014

Volltextzugriff (PDF)

Leptomeningeal metastases in non-small-cell lung cancer

The lancet oncology, 2018-01, Vol.19 (1), p.e43-e55

2018

Volltextzugriff (PDF)

Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region

Current cancer drug targets, 2017-02, Vol.17 (2), p.169-176

2017

Volltextzugriff (PDF)

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

Cancer chemotherapy and pharmacology, 2009-07, Vol.64 (3), p.539-548

2009

Volltextzugriff (PDF)

1 – 25 von 255

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(235)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(152)
Life Sciences & Biomedicine
(148)
Humans
(124)
Oncology
(124)
Biological And Medical Sciences
(100)
Medical Sciences
(99)
Pharmacology. Drug Treatments
(80)
Antineoplastic Agents
(74)
Animals
(65)
Male
(56)
Lung Neoplasms - Drug Therapy
(54)
Female
(51)
Mice
(49)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(41)
Chemotherapy
(39)
Pharmacology & Pharmacy
(39)
Lung Neoplasms - Pathology
(37)
Aged
(34)
Liposomes
(31)
Middle Aged
(30)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Targeting Protein Translation in Human Non-Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression

Mechanisms of resistance to vascular endothelial growth factor blockade

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib

Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer

Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis

Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung

Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer

Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines

Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist‐patient treatment discussions

Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects

Leptomeningeal metastases in non-small-cell lung cancer

Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

Suchergebnisse filtern